Impel Pharmaceuticals Inc. – NASDAQ:IMPL
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 8 hours
Impel Pharmaceuticals stock price monthly change
-86.76%
month
Impel Pharmaceuticals stock price quarterly change
-92.61%
quarter
Impel Pharmaceuticals stock price yearly change
-98.89%
year
Impel Pharmaceuticals key metrics
Market Cap | 956K |
Enterprise value | 22.18M |
P/E | -0.27 |
EV/Sales | 1.28 |
EV/EBITDA | -0.14 |
Price/Sales | 1.83 |
Price/Book | -0.71 |
PEG ratio | -0.01 |
EPS | -4.05 |
Revenue | 20.98M |
EBITDA | -68.62M |
Income | -96.11M |
Revenue Q/Q | 62.97% |
Revenue Y/Y | 155.28% |
Profit margin | -920.68% |
Oper. margin | -737.12% |
Gross margin | 46.18% |
EBIT margin | -737.12% |
EBITDA margin | -326.99% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImpel Pharmaceuticals stock price history
Impel Pharmaceuticals stock forecast
Impel Pharmaceuticals financial statements
| Dec 2022 | 5.00M | -36.31M | -725.08% |
|---|---|---|---|
| Mar 2023 | 4.37M | -38.63M | -883.6% |
| Jun 2023 | 6.58M | -7.35M | -111.74% |
| Sep 2023 | 5.02M | -13.81M | -275.01% |
| 2025 | 160M | 19.92M | 12.46% |
|---|
Analysts Price target
Financials & Ratios estimates
| 2023-03-24 | -1.04 | -0.97 |
|---|---|---|
| 2023-05-12 | 0.9 | -1.27 |
| 2023-08-18 | -0.65 | -0.31 |
| Dec 2022 | 88550000 | 132.70M | 149.87% |
|---|---|---|---|
| Mar 2023 | 64729000 | 137.63M | 212.63% |
| Jun 2023 | 44807000 | 123.96M | 276.66% |
| Sep 2023 | 35073000 | 126.97M | 362.04% |
| Dec 2022 | -17.98M | -1.01M | -79K |
|---|---|---|---|
| Mar 2023 | -24.14M | -1.04M | 0 |
| Jun 2023 | -20.44M | 132K | 5K |
| Sep 2023 | -16.52M | -957K | 7.06M |
Impel Pharmaceuticals alternative data
| Aug 2023 | 160 |
|---|---|
| Sep 2023 | 160 |
| Oct 2023 | 160 |
| Nov 2023 | 160 |
| Dec 2023 | 160 |
| Jan 2024 | 160 |
| Feb 2024 | 160 |
| Mar 2024 | 160 |
| Apr 2024 | 160 |
| May 2024 | 160 |
| Jun 2024 | 160 |
| Jul 2024 | 160 |
Impel Pharmaceuticals other data
12.87%
-62.66%
of IMPL is owned by hedge funds
16
-19
3.01M
-14.89M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 575000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 208,657 | $0.08 | $16,693 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 28,632 | $0.08 | $2,291 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 209,029 | $0.11 | $22,993 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 28,682 | $0.11 | $3,155 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 87,934 | $0.29 | $25,501 | ||
Sale | VIVO CAPITAL VIII, LLC 10 percent owner | Common Stock | 12,066 | $0.29 | $3,499 | ||
Option | LEAMAN JOHN HAROLD officer: Chief Fi.. | Restricted Stock Units (RSUs) | 10,571 | N/A | N/A | ||
Option | LEAMAN JOHN HAROLD officer: Chief Fi.. | Common Stock | 10,571 | N/A | N/A | ||
Option | SHREWSBURY STEPHEN B officer: Chief Me.. | Stock Option (right to buy) | 24,606 | $1.97 | $48,474 | ||
Option | SHREWSBURY STEPHEN B officer: Chief Me.. | Common Stock | 24,606 | $1.97 | $48,474 |
| Patent |
|---|
Application Filling date: 12 Jan 2022 Issue date: 16 Jun 2022 |
Application Filling date: 1 Oct 2021 Issue date: 7 Apr 2022 |
Application Filling date: 17 Dec 2019 Issue date: 24 Mar 2022 |
Grant Filling date: 4 Jan 2019 Issue date: 22 Mar 2022 |
Grant Utility: In-line nasal delivery device Filling date: 9 Sep 2016 Issue date: 8 Mar 2022 |
Grant Utility: Medical unit dose container Filling date: 25 Nov 2019 Issue date: 7 Dec 2021 |
Grant Filling date: 2 Oct 2020 Issue date: 30 Nov 2021 |
Application Filling date: 1 Feb 2021 Issue date: 21 Oct 2021 |
Application Filling date: 13 Jan 2021 Issue date: 5 Aug 2021 |
Grant Utility: Nozzles for nasal drug delivery Filling date: 15 Dec 2017 Issue date: 18 May 2021 |
| Quarter | Transcript |
|---|---|
| Q1 2023 12 May 2023 | Q1 2023 Earnings Call Transcript |
| Q4 2022 24 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 14 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 15 Aug 2022 | Q2 2022 Earnings Call Transcript |
-
When is Impel Pharmaceuticals's next earnings date?
Unfortunately, Impel Pharmaceuticals's (IMPL) next earnings date is currently unknown.
-
Does Impel Pharmaceuticals pay dividends?
No, Impel Pharmaceuticals does not pay dividends.
-
How much money does Impel Pharmaceuticals make?
Impel Pharmaceuticals has a market capitalization of 956K and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 1794.01% to 12.65M US dollars. Impel Pharmaceuticals made a loss 129.44M US dollars in net income (profit) last year or -$0.31 on an earnings per share basis.
-
What is Impel Pharmaceuticals's stock symbol?
Impel Pharmaceuticals Inc. is traded on the NASDAQ under the ticker symbol "IMPL".
-
What is Impel Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Impel Pharmaceuticals?
Shares of Impel Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Impel Pharmaceuticals's key executives?
Impel Pharmaceuticals's management team includes the following people:
- Dr. John H. Leaman M.D. Chief Financial & Bus. Officer(age: 52, pay: $538,690)
- Dr. Stephen Bevan Shrewsbury Chief Medical Officer(age: 68, pay: $518,530)
- Mr. Adrian Adams Chairman, Chief Executive Officer & Pres(age: 74, pay: $376,920)
-
How many employees does Impel Pharmaceuticals have?
As Jul 2024, Impel Pharmaceuticals employs 160 workers.
-
When Impel Pharmaceuticals went public?
Impel Pharmaceuticals Inc. is publicly traded company for more then 4 years since IPO on 23 Apr 2021.
-
What is Impel Pharmaceuticals's official website?
The official website for Impel Pharmaceuticals is impelpharma.com.
-
Where are Impel Pharmaceuticals's headquarters?
Impel Pharmaceuticals is headquartered at 201 Elliott Avenue West, Seattle, WA.
-
How can i contact Impel Pharmaceuticals?
Impel Pharmaceuticals's mailing address is 201 Elliott Avenue West, Seattle, WA and company can be reached via phone at +20 65 681466.
Impel Pharmaceuticals company profile:
Impel Pharmaceuticals Inc.
impelpharma.comExchange:
NASDAQ
Full time employees:
160
Industry:
Biotechnology
Sector:
Healthcare
Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
201 Elliott Avenue West
Seattle, WA 98119
Seattle, WA 98119
CIK: 0001445499
ISIN: US45258K1097
CUSIP: 45258K109
